Skip to main content
NCBI home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 1999 Dec;67(6):716–722. doi: 10.1136/jnnp.67.6.716

Visual field defects associated with vigabatrin therapy

M Lawden 1, T Eke 1, C Degg 1, G Harding 1, J Wild 1
PMCID: PMC1736662  PMID: 10567485

Abstract

OBJECTIVE—To estimate the prevalence of visual field defects in patients taking the anticonvulsant drug vigabatrin and to characterise the features of visual dysfunction found.
METHODS—Thirty three unselected patients attending neurology and epilepsy clinics were identified as taking vigabatrin and asked to attend for neuro-ophthalmic evaluation. A control group of 16patients with epilepsy unexposed to vigabatrin was also evaluated. Visual fields were examined by static perimetry using a Humphrey field analyser. Patients underwent detailed ophthalmic examination, various blood tests, and brain MRI where necessary. Visual evoked responses (VERs), electro-oculograms (EOGs), and electroretinograms (ERGs) were recorded.
RESULTS—Of 31 assessable patients treated with vigabatrin, 16 (52%) had definitely abnormal visual fields, nine (29%) had fields that were inconclusive, four (13%) had normal fields, and two (6%) proved unable to cooperate with testing. In four patients some plausible cause was found for the field abnormality leaving 12patients (39%) in whom a definite bilateral field defect was found, possibly caused by vigabatrin treatment. Of 16 control patients none had definitely abnormal fields, 12 (75%) had normal fields, and four (25%) had fields that were inconclusive. The field defects associated with vigabatrin treatment showed a characteristic pattern of concentric peripheral field loss with temporal and macular sparing. The VERs and ERGs were normal. The EOG Arden Index was reduced in patients taking vigabatrin, although this returned towards normal when vigabatrin was stopped, even in the presence of persistent field defects. Multifocal ERGs recorded in two patients were abnormal, showing marked reduction in amplitude of the peripheral focal ERG.
CONCLUSIONS—Treatment with vigabatrin was associated with a high prevalence of peripheral visual field defects. This seemed to be the result of a toxic effect of vigabatrin on the retina and seemed to persist if the drug was withdrawn.



Full Text

The Full Text of this article is available as a PDF (140.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baulac M., Nordmann J. P., Lanoé Y. Severe visual-field constriction and side-effects of GABA-mimetic antiepileptic agents. Lancet. 1998 Aug 15;352(9127):546–546. doi: 10.1016/S0140-6736(05)79254-0. [DOI] [PubMed] [Google Scholar]
  2. Blackwell N., Hayllar J., Kelly G. Severe persistent visual field constriction associated with vigabatrin. Patients taking vigabatrin should have regular visual field testing. BMJ. 1997 Jun 7;314(7095):1694–1694. [PMC free article] [PubMed] [Google Scholar]
  3. Butler W. H., Ford G. P., Newberne J. W. A study of the effects of vigabatrin on the central nervous system and retina of Sprague Dawley and Lister-Hooded rats. Toxicol Pathol. 1987;15(2):143–148. doi: 10.1177/019262338701500203. [DOI] [PubMed] [Google Scholar]
  4. Crofts K., Brennan R., Kearney P., O'Connor G. Vigabatrin-induced optic neuropathy. J Neurol. 1997 Oct;244(10):666–667. doi: 10.1007/s004150050165. [DOI] [PubMed] [Google Scholar]
  5. Cubells J. F., Blanchard J. S., Smith D. M., Makman M. H. In vivo action of enzyme-activated irreversible inhibitors of glutamic acid decarboxylase and gamma-aminobutyric acid transaminase in retina vs. brain. J Pharmacol Exp Ther. 1986 Aug;238(2):508–514. [PubMed] [Google Scholar]
  6. Dieterle L., Becker E. W., Berg P. A., Berkenfeld R., Reinshagen G. Allergische Vaskulitis durch Vigabatrin. Nervenarzt. 1994 Feb;65(2):122–124. [PubMed] [Google Scholar]
  7. Eke T., Talbot J. F., Lawden M. C. Severe persistent visual field constriction associated with vigabatrin. BMJ. 1997 Jan 18;314(7075):180–181. doi: 10.1136/bmj.314.7075.180. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Elder M. J. Diazepam and its effects on visual fields. Aust N Z J Ophthalmol. 1992 Aug;20(3):267–270. doi: 10.1111/j.1442-9071.1992.tb00952.x. [DOI] [PubMed] [Google Scholar]
  9. Frumkes T. E., Nelson R. Functional role of GABA in cat retina: I. Effects of GABAA agonists. Vis Neurosci. 1995 Jul-Aug;12(4):641–650. doi: 10.1017/s0952523800008932. [DOI] [PubMed] [Google Scholar]
  10. Gibson J. P., Yarrington J. T., Loudy D. E., Gerbig C. G., Hurst G. H., Newberne J. W. Chronic toxicity studies with vigabatrin, a GABA-transaminase inhibitor. Toxicol Pathol. 1990;18(2):225–238. doi: 10.1177/019262339001800201. [DOI] [PubMed] [Google Scholar]
  11. Graham D. Neuropathology of vigabatrin. Br J Clin Pharmacol. 1989;27 (Suppl 1):43S–45S. doi: 10.1111/j.1365-2125.1989.tb03460.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Harding G. F. Severe persistent visual field constriction associated with vigabatrin. Four possible explanations exist. BMJ. 1997 Jun 7;314(7095):1694–1694. [PMC free article] [PubMed] [Google Scholar]
  13. John R. A., Rimmer E. M., Williams J., Cole G., Fowler L. J., Richens A. Micro-vacuolation in rat brains after long term administration of GABA-transaminase inhibitors. Comparison of effects of ethanolamine-O-sulphate and vigabatrin. Biochem Pharmacol. 1987 May 1;36(9):1467–1473. doi: 10.1016/0006-2952(87)90112-2. [DOI] [PubMed] [Google Scholar]
  14. Krauss G. L., Johnson M. A., Miller N. R. Vigabatrin-associated retinal cone system dysfunction: electroretinogram and ophthalmologic findings. Neurology. 1998 Mar;50(3):614–618. doi: 10.1212/wnl.50.3.614. [DOI] [PubMed] [Google Scholar]
  15. Lorenz R., Kuck H. Visuelle Störungen durch Diphenylhydantoin: Klinische und elektroophthalmologische Befunde. Klin Monbl Augenheilkd. 1988 Mar;192(3):244–247. doi: 10.1055/s-2008-1050110. [DOI] [PubMed] [Google Scholar]
  16. Ludwig B. I., Marsan C. A. Clinical ictal patterns in epileptic patients with occipital electroencephalographic foci. Neurology. 1975 May;25(5):463–471. doi: 10.1212/wnl.25.5.463. [DOI] [PubMed] [Google Scholar]
  17. Mackenzie R., Klistorner A. Severe persistent visual field constriction associated with vigabatrin. Asymptomatic as well as symptomatic defects occur with vigabatrin. BMJ. 1998 Jan 17;316(7126):233–233. [PMC free article] [PubMed] [Google Scholar]
  18. Mauguière F., Chauvel P., Dewailly J., Dousse N. No effect of long-term vigabatrin treatment on central nervous system conduction in patients with refractory epilepsy: results of a multicenter study of somatosensory and visual evoked potentials. PMS Study Multicenter Group. Epilepsia. 1997 Mar;38(3):301–308. doi: 10.1111/j.1528-1157.1997.tb01121.x. [DOI] [PubMed] [Google Scholar]
  19. Neal M. J., Cunningham J. R., Shah M. A., Yazulla S. Immunocytochemical evidence that vigabatrin in rats causes GABA accumulation in glial cells of the retina. Neurosci Lett. 1989 Mar 13;98(1):29–32. doi: 10.1016/0304-3940(89)90368-6. [DOI] [PubMed] [Google Scholar]
  20. Neal M. J., Shah M. A. Development of tolerance to the effects of vigabatrin (gamma-vinyl-GABA) on GABA release from rat cerebral cortex, spinal cord and retina. Br J Pharmacol. 1990 Jun;100(2):324–328. doi: 10.1111/j.1476-5381.1990.tb15803.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Paulus W., Schwarz G., Steinhoff B. J. The effect of anti-epileptic drugs on visual perception in patients with epilepsy. Brain. 1996 Apr;119(Pt 2):539–549. doi: 10.1093/brain/119.2.539. [DOI] [PubMed] [Google Scholar]
  22. Pedersen B., Højgaard K., Dam M. Vigabatrin: no microvacuoles in a human brain. Epilepsy Res. 1987 Jan;1(1):74–76. doi: 10.1016/0920-1211(87)90054-4. [DOI] [PubMed] [Google Scholar]
  23. Perucca E., Gram L., Avanzini G., Dulac O. Antiepileptic drugs as a cause of worsening seizures. Epilepsia. 1998 Jan;39(1):5–17. doi: 10.1111/j.1528-1157.1998.tb01268.x. [DOI] [PubMed] [Google Scholar]
  24. Perucca E., Gram L., Avanzini G., Dulac O. Antiepileptic drugs as a cause of worsening seizures. Epilepsia. 1998 Jan;39(1):5–17. doi: 10.1111/j.1528-1157.1998.tb01268.x. [DOI] [PubMed] [Google Scholar]
  25. Rao G. P., Fat F. A., Kyle G., Leach J. P., Chadwick D. W., Batterbury M. Study is needed of visual field defects associated with any long term antiepileptic drug. BMJ. 1998 Jul 18;317(7152):206–206. doi: 10.1136/bmj.317.7152.206. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Ruether K., Pung T., Kellner U., Schmitz B., Hartmann C., Seeliger M. Electrophysiologic evaluation of a patient with peripheral visual field contraction associated with vigabatrin. Arch Ophthalmol. 1998 Jun;116(6):817–819. [PubMed] [Google Scholar]
  27. Wilson E. A., Brodie M. J. Severe persistent visual field constriction associated with vigabatrin. Chronic refractory epilepsy may have role in causing these unusual lesions. BMJ. 1997 Jun 7;314(7095):1693–1693. [PMC free article] [PubMed] [Google Scholar]
  28. Wong I. C., Mawer G. E., Sander J. W. Severe persistent visual field constriction associated with vigabatrin. Reaction might be dose dependent. BMJ. 1997 Jun 7;314(7095):1693–1694. [PMC free article] [PubMed] [Google Scholar]
  29. Wu S., Sutter E. E. A topographic study of oscillatory potentials in man. Vis Neurosci. 1995 Nov-Dec;12(6):1013–1025. doi: 10.1017/s0952523800006696. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES